Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2003
09/18/2003US20030175270 Suppression of Janus kinase and signal transducers and acitavators of transcription (JAK/STAT), by administering monoclonal antibodies; immunology
09/18/2003US20030175269 Light and heavy chain peptides, used as antagonists of CD antigen or membrane proteins, for prophylaxis of autoimmune diseases
09/18/2003US20030175267 Method for the treatment of inflammatory joint disease
09/18/2003US20030175266 Peptides having amino acid sequences or fragments from human proteins, used as antitumor, anticarcinogenic and/or antiproliferative agents
09/18/2003US20030175265 Chandra: a novel Th1-specific gene
09/18/2003US20030175264 Comprises proteolytic enzymes; free of plasminogen activator
09/18/2003US20030175263 Modification of vitreal matrix metalloproteinase activity
09/18/2003US20030175262 Mammalian adhesion protease peptides
09/18/2003US20030175261 Captopril; hyaluronidases; phospholipases
09/18/2003US20030175259 Use of corneal hardening agents in enzymeorthokeratology
09/18/2003US20030175257 Cartilage regeneration using chondrocyte and TGF-beta
09/18/2003US20030175256 Allografts comprising undifferentiated fetal skin cells integrated within collagen matrix
09/18/2003US20030175252 Therapeutic compounds for ovarian cancer
09/18/2003US20030175249 For labeling/activating antigen presenting cells; chaperone proteins
09/18/2003US20030175246 Toxin-phage bacteriocide antibiotic and uses thereof
09/18/2003US20030175245 Replication deficient adenoviral TNF vector
09/18/2003US20030175243 Blocking receptor binding; gene therapy; gastrin releasing peptide
09/18/2003US20030175241 Interferon-beta variants and conjugates
09/18/2003US20030175240 Interferon-beta variants and conjugates
09/18/2003US20030175238 Chemokine conjugates
09/18/2003US20030175231 Contacting epidermal melanocytes with a peptide having amino acid sequence lysine-glycine- alanine to inhibit cell loss, which binds to p75 nerve growth factor receptor expressed on the surface of the melanocytes
09/18/2003US20030175214 Free-flowing fine particle mixtures comprising carrier particles, active drug particles and stabilizer particles, for respiratory system disorders; medical equipment
09/18/2003US20030175212 Use of soluble gammadelta T cell receptors for regulating T cell function
09/18/2003US20030175210 Individualization of therapy with anxiolitics
09/18/2003US20030175208 Treating a cancer of the immune system
09/18/2003US20030175207 A chelated complex comprised of lantibiotics and a transition or lanthanide metal, for a chemiluminescent assay of bacteria or fungi; binding to grampositive or mycobacterial cells or gramnegative bacteria
09/18/2003US20030175205 Comprising a radioactive materials for detecting and/or quantifying diseases or conditions associated with cancer, infections, inflammation; a 2-propane carboxylic ester with a attached phosphatidic acid group
09/18/2003US20030173219 Devices and formulations
09/18/2003DE20121877U1 Module for suppressing leukocyte activity, useful e.g. in association with heart-lung machines, comprises a carrier linked to a ligand specific for the leukocyte receptor
09/18/2003CA2813780A1 Genetic products differentially expressed in tumors and use thereof
09/18/2003CA2671976A1 Methods of inducing terminal differentiation
09/18/2003CA2518248A1 Proteolysis-resistant active vegf
09/18/2003CA2478827A1 Remedies for sex hormone-dependent disease
09/18/2003CA2478675A1 Inhibitors for use in hemostasis
09/18/2003CA2478604A1 Cancer-linked gene as target for chemotherapy
09/18/2003CA2478593A1 Cancer-linked gene as target for chemotherapy
09/18/2003CA2478592A1 Genomic screen for epigenetically silenced genes associated with cancer
09/18/2003CA2478510A1 Genomic screen for epigenetically silenced tumor suppressor genes
09/18/2003CA2478479A1 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phagebeta protein, or hydroxyurea
09/18/2003CA2478413A1 Genetic products differentially expressed in tumors and use thereof
09/18/2003CA2478412A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same
09/18/2003CA2478369A1 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
09/18/2003CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
09/18/2003CA2478239A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
09/18/2003CA2478177A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
09/18/2003CA2478118A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
09/18/2003CA2478032A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/18/2003CA2477932A1 Use of egfr transactivation inhibitors in human cancer
09/18/2003CA2477780A1 Methods of enhancing immune induction involving mda-7
09/18/2003CA2477577A1 Interferon beta-like molecules for treatment of stroke
09/18/2003CA2477256A1 Methods for aneurysm repair
09/18/2003CA2476567A1 A process for the production of ramoplanin-like amide derivatives
09/18/2003CA2476183A1 Treatment of type i diabetes mellitus using growth hormone antagonist
09/18/2003CA2475738A1 Activated protein c formulations
09/18/2003CA2474613A1 Sustained release drug formulations containing a carrier peptide
09/18/2003CA2449341A1 Novel proteins and nucleic acids encoding same
09/17/2003EP1344826A1 Materials comprising and methods of preparation and use for ribosome - inactivating proteins
09/17/2003EP1344825A1 Fohy030 test kits
09/17/2003EP1344824A1 Mutated gene coding for a LAT protein and the biological applications thereof
09/17/2003EP1344823A1 Novel g protein-coupled receptor proteins and dnas thereof
09/17/2003EP1344821A1 Novel aggrecanase
09/17/2003EP1344819A2 Human hematopoietic stem cell
09/17/2003EP1344773A1 Growth hormone secretagogues
09/17/2003EP1344536A1 Method of regulating the activity of expression product of gene transferred into living body
09/17/2003EP1344533A1 Pharmaceutical compositions comprising mannose binding lectin
09/17/2003EP1344532A1 High molecular weight kininogen (HK) domain 5 derived peptides against thrombic diseases
09/17/2003EP1344531A1 High molecular weight kininogen (HK) domain 5 derived peptides against thrombic diseases
09/17/2003EP1344530A1 Interleukin-18 inducing agent
09/17/2003EP1344521A1 Procedure for reconstitution of lyophilized proteins
09/17/2003EP1344064A2 Compositions and methods relating to prostate specific genes and proteins
09/17/2003EP1344063A1 A screening assay for antagonists of human leukocyte receptors
09/17/2003EP1343913A2 Antisense modulation of src-2 expression
09/17/2003EP1343903A1 A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
09/17/2003EP1343900A2 Oxidoreductases
09/17/2003EP1343896A1 Small acid-soluble spore protein and uses thereof
09/17/2003EP1343895A2 Streptococcus pyogenes antigens and corresponding dna fragments
09/17/2003EP1343891A2 Colon cancer marker
09/17/2003EP1343887A2 Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
09/17/2003EP1343886A2 Compositions and methods for the therapy and diagnosis of lung cancer
09/17/2003EP1343885A2 Molecules for disease detection and treatment
09/17/2003EP1343876A2 Modulators of activity of g-protein-coupled receptor kinases
09/17/2003EP1343822A2 Means for the diagnosis and therapy of ctcl
09/17/2003EP1343818A1 Modified tachykinin receptors
09/17/2003EP1343816A2 PROTEINS THAT INTERACT WITH $g(b)TRCP
09/17/2003EP1343815A2 Antibacterial treatments
09/17/2003EP1343813A1 Novel compounds
09/17/2003EP1343811A1 Methods for preparing purified lipopeptides
09/17/2003EP1343810A2 Diaminodicarboxylic acid: peptide-based gemini surfactant compounds used for drug delivery
09/17/2003EP1343807A2 Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
09/17/2003EP1343805A1 Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
09/17/2003EP1343542A2 Carrier with solid fibrinogen and solid thrombin
09/17/2003EP1343524A1 Vaccine based on a cellular penetration factor from an apicomplexan parasite
09/17/2003EP1343523A2 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings
09/17/2003EP1343522A2 Procollagen (iii) propeptides and related substances for treating fibrotic diseases
09/17/2003EP1343521A2 Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations
09/17/2003EP1343520A2 New therapeutic uses of smr1 peptides
09/17/2003EP1343519A2 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
09/17/2003EP1343518A2 Stabilized inteferon compositions
09/17/2003EP1343517A2 Survical promoting ncam binding and ncam ligand biding compounds
09/17/2003EP1343516A2 Analogues of thiocoraline and be-22179
1 ... 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 ... 3163